Water Soluble Curcumin-Based Compounds
    2.
    发明申请
    Water Soluble Curcumin-Based Compounds 审中-公开
    水溶性姜黄素类化合物

    公开(公告)号:US20100316631A1

    公开(公告)日:2010-12-16

    申请号:US12446375

    申请日:2007-10-19

    申请人: Ahmad Safavy

    发明人: Ahmad Safavy

    CPC分类号: A61K36/9066

    摘要: The present disclosure describes the design and synthesis of a novel class of water soluble curcumin-based compounds. These water soluble curcumin-based compounds are shown to provide superior cell killing activity and exhibit increased and cell internalization solubility in aqueous solutions as compared to the free (unconjugated) curcumin. The present disclosure provides compositions for the treatment or prevention of a variety of disease states or conditions, such as but not limited to, cancer, other cell hyperproliferative disorders and chronic inflammatory conditions, said compositions comprising a water soluble curcumin-based compound.

    摘要翻译: 本公开描述了一类新型水溶性姜黄素类化合物的设计和合成。 与游离(非共轭)姜黄素相比,这些水溶性姜黄素类化合物显示出提供优异的细胞杀伤活性,并且在水溶液中表现出增加的细胞内化溶解度。 本公开提供了用于治疗或预防各种疾病状态或病症(例如但不限于癌症,其他细胞过度增殖性病症和慢性炎性病症)的组合物,所述组合物包含水溶性姜黄素基化合物。

    Combretastatin analogs with tubulin binding activity
    3.
    发明授权
    Combretastatin analogs with tubulin binding activity 有权
    具有微管蛋白结合活性的Combretastatin类似物

    公开(公告)号:US07429681B2

    公开(公告)日:2008-09-30

    申请号:US11454074

    申请日:2006-06-14

    IPC分类号: C07C49/172 A01N35/06

    摘要: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.

    摘要翻译: 已经发现了考布他汀的类似物,其表现出令人印象深刻的细胞毒性以及抑制微管蛋白聚合的显着能力。 这些化合物是治疗人类癌症的极好临床候选物。 此外,作为前药的这些配体中的某些可以很好地证明是肿瘤选择性血管靶向化学治疗剂或具有导致选择性预防和/或破坏非恶性增殖血管的血管靶向活性。